ArticleJournal of neurosurgery. Case lessons2025
Utility of [18F]fluciclovine PET/MRI for identifying the optimal biopsy target region, helping to avoid underdiagnosis in patients with glioblastoma: illustrative case.
Article in Journal of neurosurgery. Case lessons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of small distant glioblastoma lesions using 18F-fluciclovine positron emission tomography: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) is known for its significant intratumoral heterogeneity, making biopsies susceptible to underdiagnosis if samples are taken from less malignant regions. [18F]Fluciclovine, a novel PET tracer, has demonstrated high accumulation in glioma tissue, with minimal uptake in normal brain tissue. OBSERVATIONS: A 50-year-old woman presented with sensory aphasia. MRI revealed a FLAIR lesion extending from the left parietal to the medial temporal lobe. [18F]Fluciclovine PET/MRI identified two areas of increased uptake, both FLAIR negative. Stereotactic biopsy was used to obtain samples from PET-positive (PET+) and FLAIR-positive (FLAIR+) lesions. Pathological analysis of the PET+ lesion revealed densely proliferating tumor cells with irregularly enlarged nuclei, while the FLAIR+ lesion exhibited sparsely proliferating cells. Molecular analysis showed that both lesions were IDH wildtype with MGMT promoter hypomethylation. Sanger sequencing identified a telomerase reverse transcriptase promoter -124 C>T mutation in the PET+ lesion but not in the FLAIR+ lesion. The integrated diagnosis, based primarily on the PET+ lesion, was GBM, IDH wildtype. LESSONS: This case highlights the importance of [18F]fluciclovine PET/MRI in identifying high-cell-density regions, minimizing the risk of underdiagnosis in GBM. Further studies are necessary to evaluate its prognostic value in GBM management. https://thejns.org/doi/10.3171/CASE24677.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.